Compare
Propanc Biopharma, Inc. vs NRX Pharmaceuticals, Inc. vs Imunon, Inc. vs Turn Therapeutics Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | NRX Pharmaceuticals, Inc. NRXP | Imunon, Inc. IMNN | Turn Therapeutics Inc. TTRX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.45M | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | 65.1% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$18.86M | -$28.62M | -$14.50M | -$3.19M |
| EPS (Diluted) | -$17.62 | n/a | -$6.83 | -$0.12 |
| Operating cash flow | -$5.68M | -$14.11M | -$13.90M | -$2.56M |
| Free cash flow | -$5.69M | n/a | -$14.18M | n/a |
| Cash & equivalents | n/a | $7.80M | $8.78M | $4.03M |
| Total assets | $12.78M | $12.96M | $12.29M | $12.16M |
| Total liabilities | $3.38M | $28.89M | $5.23M | $7.48M |
| Shareholders' equity | $9.40M | -$15.94M | $7.06M | $4.69M |
| Return on year-end equity | -200.6% | n/a | -205.3% | -68.2% |
| Shares outstanding | 3.31M | 31.73M | 3.42M | 29.45M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | NRX Pharmaceuticals, Inc. | Imunon, Inc. | Turn Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.45M Ended 2025-12-31 | $500.0K Ended 2022-12-31 | n/a |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $500.0K Ended 2021-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $500.0K Ended 2020-12-31 | n/a |
| 3 years earlier | n/a | n/a | $500.0K Ended 2019-12-31 | n/a |
| 4 years earlier | n/a | n/a | $500.0K Ended 2018-12-31 | n/a |